FDA Approves 1st mRNA Flu Shot, From Moderna
The FDA has approved the first mRNA flu shot, mFlusiva, from Moderna. The vaccine was found to be 27% more effective than a standard flu shot in a late-stage trial.
Intelligence analysis by Llama
The FDA has approved the first mRNA flu shot, mFlusiva, from Moderna. The vaccine was found to be 27% more effective than a standard flu shot in a late-stage trial. The approval comes after a late-stage clinical trial of over 40,000 older adults across 11 countries, including the US. The vaccine was found to have mild to moderate side effects, including injection-site pain, fatigue, a…
Imagine you have a special kind of messenger that helps your body fight off the flu. That's basically what an mRNA flu shot is. It sends a message to your body to help it fight off the flu virus. This type of shot is new and uses a different kind of technology than traditional flu shots.
Analysis
A Breakthrough in Flu Vaccine Technology
The FDA's approval of mFlusiva marks a significant breakthrough in flu vaccine technology. The use of mRNA technology allows for faster manufacturing and better matching of circulating influenza strains. This is particularly important for the flu, which puts hundreds of thousands of people in the hospital every year and can result in tens of thousands of deaths.
Why mRNA Technology Matters
mRNA technology has been touted as a game-changer in the field of vaccine development. It allows for faster manufacturing and better matching of circulating influenza strains. This is because mRNA vaccines can be manufactured much faster than traditional vaccines, allowing scientists to better match circulating influenza strains. Moderna said it takes two to three months from picking the strain to rolling out its flu shot, compared with about six months for traditional flu shots.
The Road Ahead
Despite the approval of mFlusiva, there are still concerns about its use. Health and Human Services Secretary Robert F. Kennedy Jr. has repeatedly criticized mRNA technology, calling the Covid vaccines 'the deadliest vaccine ever made.' Additionally, the FDA initially refused to review Moderna's application before reversing course a week later. This has raised concerns about the safety and efficacy of the vaccine.
Key points
- The FDA has approved the first mRNA flu shot, mFlusiva, from Moderna.
- The vaccine was found to be 27% more effective than a standard flu shot in a late-stage trial.
- The approval comes after a late-stage clinical trial of over 40,000 older adults across 11 countries, including the US.
- The vaccine was found to have mild to moderate side effects, including injection-site pain, fatigue, and headaches.
If mFlusiva is widely adopted, it could lead to a significant reduction in flu-related hospitalizations and deaths. Additionally, the use of mRNA technology could lead to faster development of new vaccines, allowing scientists to better match circulating influenza strains.
One concern is that the FDA's approval of mFlusiva may be seen as a victory for the pharmaceutical industry, which could lead to increased profits at the expense of public health. Additionally, the use of mRNA technology has been criticized by some, who argue that it is not yet fully understood.
